Does a single-pill antihypertensivelipid-lowering regimen improve adherence in us managed care enrolees? A non-randomized, observational, retrospective study

American Journal of Cardiovascular Drugs

Volumn 10, Issue 3, 2010, Pages 193-202

  Hussein, Mohamed A ^a   Chapman, Richard H ^a   Benner, Joshua S ^a   Tang, Simon S K ^b   Solomon, Henry A ^b   Joyce, Amie ^c   Foody, Joanne M ^d  

^a IMS Consulting   (United States)

^b PFIZER INC   (United States)

^c IMS   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MORBIDITY; PATIENT COMPLIANCE; PHARMACY; PILL; PRIORITY JOURNAL; UNITED STATES; AGED; DRUG COMBINATION; HEALTH INSURANCE; HYPERCHOLESTEROLEMIA; HYPERTENSION; MIDDLE AGED; RETROSPECTIVE STUDY; RISK;

ADULT; AGED; AMLODIPINE; CALCIUM CHANNEL BLOCKERS; DRUG THERAPY, COMBINATION; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; MANAGED CARE PROGRAMS; MEDICATION ADHERENCE; MIDDLE AGED; ODDS RATIO; PYRROLES; RETROSPECTIVE STUDIES;

EID: 77953236144     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/11530680-000000000-00000     Document Type: Article

References (40)

1. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch InternMed 2005; 165 (10): 1147-1152
2. Vrijens B, Vincze G, Kristanto P, et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 2008; 336 (7653): 1114-1117
3. Ho PM, MagidDJ, Shetterly SM, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J 2008; 155 (4): 772-779
4. Parris ES, Lawrence DB, Mohn LA, et al. Adherence to statin therapy and LDL cholesterol goal attainment by patients with diabetes and dyslipidemia. Diabetes Care 2005; 28 (3): 595-599
5. Bramley TJ,Gerbino PP, Nightengale BS, et al. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm 2006; 12 (3): 239-245
6. Fung V, Huang J, Brand R, et al. Hypertension treatment in a Medicare population: adherence and systolic blood pressure control. Clin Ther 2007; 29 (5): 972-984
7. Ho PM, Magid DJ, Shetterly SM, et al. Importance of therapy intensification and medication nonadherence for blood pressure control in patients with coronary disease. Arch Intern Med 2008; 168 (3): 271-276
8. DiMatteo MR, Giordani PJ, Lepper HS, et al. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care 2002; 40 (9): 794-811
9. Frishman WH. Importance of medication adherence in cardiovascular disease and the value of once-daily treatment regimens. Cardiol Rev 2007; 15 (5): 257-263
10. Gehi AK, Ali S, Na B, et al. Self-reported medication adherence and cardiovascular events in patients with stable coronary heart disease: the Heart and Soul Study. Arch Intern Med 2007; 167 (16): 1798-1803
11. Sokol MC, McGuigan KA, Verbrugge RR, et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005; 43 (6): 521-530
12. Wei L, Wang J, Thompson P, et al. Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart 2002; 88 (3): 229-233
13. Dezii CM. A retrospective study of persistence with single-pill combination therapy vs concurrent two-pill therapy in patients with hypertension. Manag Care 2000; 9 (9 Suppl.): 2-6
14. Taylor AA, Shoheiber O. Adherence to antihypertensive therapy with fixeddose amlodipine besylate/benazepril HCl versus comparable componentbased therapy. Congest Heart Fail 2003; 9 (6): 324-332
15. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120 (8): 713-719
16. KiortsisDN,Giral P, Bruckert E, et al. Factors associated with low compliance with lipid-lowering drugs in hyperlipidemic patients. J Clin Pharm Ther 2000; 25 (6): 445-451
17. Piette JD, Heisler M, Wagner TH. Cost-related medication underuse among chronically ill adults: the treatments people forgo, how often, and who is at risk. Am J Public Health 2004; 94 (10): 1782-1787
18. Taira DA, Wong KS, Frech-Tamas F, et al. Copayment level and compliance with antihypertensive medication: analysis and policy implications for managed care. Am J Manag Care 2006; 12 (11): 678-683
19. Agarwal S, Tang SSK, Rosenberg N, et al. Does synchronizing initiation of therapy affect adherence to concomitant use of antihypertensive and lipidlowering therapy? Am J Ther 2009 Mar-Apr; 16 (2): 119-126
20. Blank R, LaSalle J, Reeves R, et al. Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the Amlodipine/Atorvastatin Gemini Study). J Clin Hypertens (Greenwich) 2005; 7 (5): 264-273
21. Flack JM, Victor R, Watson K, et al. Improved attainment of blood pressure and cholesterol goals using single-pill amlodipine/atorvastatin in African Americans: the CAPABLE trial. Mayo Clin Proc 2008; 83 (1): 35-45
22. Patel BV, Leslie RS, Thiebaud P, et al. Adherence with single-pill amlodipine/ atorvastatin vs a two-pill regimen. VascHealth Risk Manag 2008; 4 (3): 673-681
23. Dolovich L, Nair K, Sellors C, et al. Do patients' expectations influence their use ofmedications? Qualitative study. Can Fam Physician 2008; 54 (3): 384-393
24. Poluzzi E, Strahinja P, Vaccheri A, et al. Adherence to chronic cardiovascular therapies: persistence over the years and dose coverage. Br J Clin Pharmacol 2007; 63 (3): 346-355
25. Davis KL, Candrilli SD, Edin HM. Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population. Epilepsia 2008; 49 (3): 446-454
26. Joyce AT, Harrison DJ, Loebel AD, et al. Effect of initial ziprasidone dose on length of therapy in schizophrenia. Schizophr Res 2006; 83 (2-3): 285-292
27. Siegel D, Lopez J, Meier J. Antihypertensive medication adherence in the Department of Veterans Affairs. Am J Med 2007; 120 (1): 26-32
28. D'Agostino Jr RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17 (19): 2265-2281
29. Hirano K, Imbens G. Estimation of causal effects using propensity score weighting: an application to data on right heart catheterization. Health Serv Outcomes Res Methodol 2001; 2: 259-278
30. Thiebaud P, Patel BV, Nichol MB, et al. The effect of switching on compliance and persistence: the case of statin treatment. Am JManag Care 2005; 11 (11): 670-674
31. Pan F, Chernew ME, Fendrick AM. Impact of fixed-dose combination drugs on adherence to prescriptionmedications. J Gen InternMed 2008; 23 (5): 611-614
32. Morris AB, Li J, Kroenke K, et al. Factors associated with drug adherence and blood pressure control in patients with hypertension. Pharmacotherapy 2006; 26 (4): 483-492
33. Chung M, Calcagni A, Glue P, et al. Bioavailability of amlodipine besylate/ atorvastatin calcium combination tablet. J Clin Pharmacol 2006; 46 (9): 1030-1037
34. Preston RA, Harvey P, Herfert O, et al.A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the Respond Trial. J Clin Pharmacol 2007; 47 (12): 1555-1569
35. Benner JS, Chapman RH, Petrilla AA, et al. Association between prescription burden and medication adherence in patients initiating antihypertensive and lipid-lowering therapy. Am J Health Syst Pharm 2009; 66 (16): 1471-1477
36. van Zwieten PA. Amlodipine: an overview of its pharmacodynamic and pharmacokinetic properties. Clin Cardiol 1994; 17 (9 Suppl. 3): III3-6
37. Newman CB, Palmer G, Silbershatz H, et al. Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. Am J Cardiol 2003; 92 (6): 670-676
38. Detry JM, Block P, De Backer G, et al. Patient compliance and therapeutic coverage: comparison of amlodipine and slow release nifedipine in the treatment of hypertension. The Belgian Collaborative Study Group. Eur J Clin Pharmacol 1995; 47 (6): 477-481
39. Insull W, Kafonek S, Goldner D, et al. Comparison of efficacy and safety of atorvastatin (10 mg) with simvastatin (10 mg) at six weeks. ASSET Investigators. Am J Cardiol 2001; 87 (5): 554-559 (Pubitemid 32178449)
40. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997; 50 (1): 105-116